Stable pharmaceutical composition for treating neurogenic detrusor overactivity, comprises mirabegron or its salt and sodium polystyrene sulfonate, where pharmaceutical composition does not contain magnesium stearate and/or calcium stearate
	SINGH S; KHARABE G; RIZWAN M D; SANDAL R; TALLAM S; PANDEY A K
	2023-10-11
专利权人	ALKEM LAB LTD (ALKE-Non-standard)
申请日期	2023-10-11
专利号	IN202321068333-A
成果简介	NOVELTY - A stable pharmaceutical composition comprises mirabegron or its salt and sodium polystyrene sulfonate, where the pharmaceutical composition does not contain magnesium stearate and/or calcium stearate. USE - Stable pharmaceutical composition for treating neurogenic detrusor overactivity (claimed) in pediatric patients aged 3 years and older. No biological data given. ADVANTAGE - The composition has improved solubility, improved dissolution rate, stability and manufacturing process and improved patient compliance, and is stable for at least 24 hours at 25±2℃/60±5% relative humidity.
IPC 分类号	A61K-031/426 ; A61K-047/14 ; A61K-047/30 ; A61K-009/00 ; A61P-013/10
国家	印度
专业领域	医药卫生
语种	英语
成果类型	专利
文献类型	科技成果
条目标识符	http://119.78.100.226:8889/handle/3KE4DYBR/20030
专题	中国科学院新疆生态与地理研究所
作者单位	ALKEM LAB LTD (ALKE-Non-standard)
推荐引用方式 GB/T 7714	SINGH S,KHARABE G,RIZWAN M D,et al. Stable pharmaceutical composition for treating neurogenic detrusor overactivity, comprises mirabegron or its salt and sodium polystyrene sulfonate, where pharmaceutical composition does not contain magnesium stearate and/or calcium stearate. IN202321068333-A[P]. 2023.

条目包含的文件
条目无相关文件。

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。